Management

Thomas A. Smeenk

President & CEO, Co-Founder

Founder, President and VP Business Development, TheraVitae Inc., which went public as Hemostemix Inc. QT.
A finance and business development executive with a proven track record of bringing new discoveries to market.
A public company executive since 1996, serving most recently as President & CEO of Broadway Gold Mining Ltd, where he completed a $30 million agreement with Rio Tinto. Prior, VP Business Development, Memex Inc. (TSXV:MEM); President & CEO of e-Manufacturing Networks Inc. (TSXV:OEE); President and CEO of Tyranex Gold Inc. and President and CEO of IBI Corporation
linkedin https://www.linkedin.com/in/thomas-smeenk-03b9213/?originalSubdomain=ca

Dr. Fraser Henderson

Chief Medical Officer

Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis Health at Doctors Hospital, staff at University of Maryland Capitol Region Medical Center and Director of the Chiari Syringomyelia Foundation Greater Metropolitan Washington Chapter, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in genetic disorders of the craniocervical junction. He was recipient of the American Association of Neurological Surgeons/CNS Award for Excellence in Spine Research in 2007, and the RISES Physicians award at The Adventist Shady Grove Hospital in 2011. The inventor of 13 patents relating to disorders of the brainstem and spinal cord, Dr. Henderson has published over 100 peer reviewed articles and book chapters, and given over 190 invited lectures with a focus on craniocervical disorders, genetic disorders, cancer, radiosurgery and unusual problems of the spine.

Richard Groome

Special Advisor To The CEO

Mr. Groome thrives on innovation and disruption and has been involved in numerous highly successful innovators over the last 38 years. He believes with a driven and devoted team, positive disruption can be achieved through innovation, perseverance and good governance scaled globally. He has been relentless in his efforts to identify and recognize opportunities over the years and has been the catalyst to help dozens of companies in fintech, agriculture, medical and biotechnology, new mineral technologies, and retail.

Dr. Mary Argent-Katwala

Manager, Clinical Trials

• Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK. Dr. Argent-Katwala was Director, Diagnosis & Clinical Care at the Canadian Partnership Against Cancer, Toronto, ON where she created a portfolio of high-impact investments to address key issues in the diagnosis and treatment of cancer.Prior to joining the Partnership, Dr. Argent-Katwala held progressive positions with the Decision Resources Group in both Toronto. ON and London, UK, with her most recent assignment being Vice President, Therapy, Reports & Consulting. Dr. Argent-Katwala directed teams analyzing market dynamics, patterns of care and emerging therapies across all therapeutic areas in the G7 and BRIC regions for clients in the pharma, biotech and medical device industries.“Dr. Argent-Katwala is a great addition to our team,” said Thomas Smeenk, President & CEO. “She has a complete understanding of the science of ACP-01, the track record of generating meaningful analyses of each of our markets to help us focus trials in our key revenue streams, and combines that with the relationship-based experience from which to inspire confidence in our partnerships and our clinical trial programs,” Smeenk said.“I’m delighted to join Hemostemix at this exciting time for the company and I look forward to advancing the development of ACP-01 and bringing hope to patients and their families,” said Dr. Argent-Katwala.